Takeda Bio Development Center (Takeda Bio), a wholly owned subsidiary of Takeda, has initiated the Japanese portion of the trial and will lead AMG 479’s development in Japan.
Discovered and developed by Amgen, AMG 479 suppresses tumor cell growth and invasion by inhibiting the binding of IGF-1 and IGF-2 to its receptor (IGF-1R).
The trial is a randomized, double-blind trial of gemcitabine plus AMG 479 or placebo in about 825 patients with metastatic pancreas cancer.
The primary endpoint is overall survival.
Takeda Bio president Hiroyasu Nakamura said they will devote themselves to progress AMG 479’s development so that they can offer a novel treatment option for patients with pancreas cancer.